Its design includes parallel arms and aims to assess whether the addition of tirzepatide may be beneficial for both joint outcomes and weight/metabolic parameters in this particular PsA population
Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity
Maintaining weight loss in the long term could actually slow down or even reverse obesity-related issues
In the SUSTAIN program, 83 patients (1.4%) treated with semaglutide developed a gallbladder event, compared with 39 patients (1.9%) in the placebo group ( versus 0.1% with placebo), while the risk of cholecystitis was similar (data derived from the summary of product characteristics (SmPC) (87), as the manuscripts did not describe these data)
In short, it's your body's built-in "I've eaten, stay balanced" signal
Semaglutide and hair loss Semaglutide has the most real-world data on hair loss